✎GSK RSV疫苗获FDA批准扩大适用人群至50-59岁 2024年6月7日,葛兰素史克(GSK)宣布,FDA批准重组呼吸道合胞病毒(RSV)疫苗Arexvy的适用范围扩大到50-59岁的RSV高危成人。 这是首款保护50-59岁高危人群的RSV疫苗。2023年,Arexvy先后在...
Tannen说:“现在一家主要法院已经认定这些专利无效,GSK在美国以类似理由提起的专利侵权诉讼可能会面临更大的挑战。辉瑞以GSK的专利显而易见为由进行抗辩,这可能会在其他法院获得支持,从而破坏GSK的法律策略。GSK不太可能赢得这场法律战,因此全球RSV疫苗市场不...
对LNPs脂质成分和/或比例进行多种修饰，实现其优先在特定器官中积累的特性，Goswami等人表明，甘露糖化胆固醇可改善抗RSV自扩增mRNA疫苗（SAM）的内化和效力，一些MR靶向siRNA的例子（配体直接连接到siRNA 或siRNA包封颗粒）也被报道。图2 LNP 结构、组成和靶向配体加入策略 五、结论 靶向先天免疫相关细胞上的特异性受体...
We are also exploring ways to protect against a broader range of respiratory viruses using advanced vaccine technologies, such as adjuvants and next-generation mRNA. 02 / 02 Behind the science Three facts scientists have learned about RSV – and why sharing them could help protect those most ...
目前,全球在研RSV疫苗达60余款,GSK的重组蛋白疫苗已率先撞线,辉瑞的重组蛋白疫苗也呼之欲出;Moderna的RSV mRNA疫苗III期临床已达到主要终点,将在今年递交上市申请。GSK疫苗虽具有先发优势,不过谁能占据更大的市场份额仍然是个未知数。 GSK3844766A:更优的疗效 ...
Safety and efficacy of mRNA-1345, an mRNA-based vaccine against respiratory syncytial virus, in adults 60 years and older (oral presentation). Presented at RSSVW'23, 22-24 February 2023, Lisbon, Portugal. https://s29.q4cdn.com/435878511/files/doc_downloads/program_detail/2023/09/RSV-09-...
GSK releases strong efficacy data for older adult vaccine candidate RSV OA ahead of IDWeek2022 conference presentation.
对LNPs脂质成分和/或比例进行多种修饰,实现其优先在特定器官中积累的特性,Goswami等人表明,甘露糖化胆固醇可改善抗RSV自扩增mRNA疫苗(SAM)的内化和效力,一些MR靶向siRNA的例子(配体直接连接到siRNA 或siRNA包封颗粒)也被报道。 图2 LNP 结构、组成和靶向配体加入策略 ...
在全球RSV疫苗市场,除辉瑞和GSK外,Moderna的RSV疫苗MRNA-1345也已于今年7月在多国申请上市,用于预防60岁或以上成人RSV相关下呼吸道疾病(RSV-LRTD)和急性呼吸道疾病(ARD)的疫苗。 参考资料: [1]GSK Looks to Push RSV Vaccine to Younger Seniors with New Phase III Data. Published: Oct 25, 2023 By Trist...
Infectious Diseases: FDA approval for Arexvy in adults aged 50-59 at increased risk from RSV; filings accepted for meningitis (ABCWY) vaccine HIV: regimen selection for CAB-ULA, and data for new 3rd generation integrase inhibitor, support portfolio progression and long-term growth outlo...